终末期肾病患者无症状颈动脉疾病不应推荐颈动脉内膜切除术
基于美国肾脏数据系统2008-2014年数据,分析1813例因无症状颈动脉疾病行颈动脉内膜切除术的透析终末期肾病患者,3年生存率低,即使低风险组3年生存率也仅58.5%-58.8%,风险分层和术后药物管理未识别出3年生存率足够的亚组,因此这些患者无法实现颈动脉内膜切除术的预防获益。
要点
- 终末期肾病透析患者因无症状颈动脉疾病行颈动脉内膜切除术,整体长期生存率低。
- 即使Liu合并症指数≤8组,3年生存率仅58.8%(95%CI 53.9-63.4)。
- 风险评分低危组3年生存率58.5%(95%CI 54.9-61.9),风险分层未识别出生存足够亚组。
核心结论
- 终末期肾病患者因无症状颈动脉疾病行颈动脉内膜切除术的长期生存率低,风险分层和术后药物管理分析未识别出3年生存率足够的亚组,因此这些患者未实现颈动脉内膜切除术的预防获益。
研究设计与样本
- 回顾性队列研究,纳入美国肾脏数据系统中2008-2014年因无症状颈动脉疾病行颈动脉内膜切除术的透析终末期肾病患者1813例。
- 使用Liu合并症指数和基于Cox比例风险模型的新型风险预测模型进行风险分层。
- 主要结局为3年生存率,采用Kaplan-Meier法估计;并对1249例(占总68.8%)有Medicare part D数据的患者进行术后药物使用亚组分析。
主要发现
- 人群以老年人为主(平均年龄70.2±9.1岁),白人占84.8%,高血压占90.7%,糖尿病占62.5%,充血性心力衰竭占35.4%。
- Liu合并症指数≤8者占23.0%,9-12者占35.0%,>12者占42.0%;Liu指数升高与生存更差相关(P<0.01),但指数≤8组3年生存率仅58.8%(95%CI 53.9-63.4)。
- Cox模型识别年龄>80岁(aHR=2.49,95%CI 1.87-3.33,P<0.001)、充血性心力衰竭(aHR=1.31,95%CI 1.14-1.51,P<0.001)、Liu合并症指数>12(aHR=1.89,95%CI 1.56-2.28,P<0.001)等变量。
- 风险评分范围0-6.5,分为≤2分(43.4%)、2-4分(41.2%)、>4分(15.4%)三组;评分升高与生存更差相关(P<0.01),但低危组3年生存率仅58.5%(95%CI 54.9-61.9)。
- Part D亚组分析发现他汀类和钙通道阻滞剂使用与生存改善相关,但用药患者观察率仍低。
关键数值与推荐
- 无症状颈动脉疾病行颈动脉内膜切除术的建议适用于围手术期卒中风险低且预期寿命3-5年的患者。
- 年龄>80岁aHR=2.49(95%CI 1.87-3.33,P<0.001)。
- 充血性心力衰竭aHR=1.31(95%CI 1.14-1.51,P<0.001)。
- Liu合并症指数>12 aHR=1.89(95%CI 1.56-2.28,P<0.001)。
临床怎么用
- 原文结论未给出具体临床推荐,仅指出风险分层和术后药物管理分析未识别出3年生存率足够的亚组,预防获益未实现。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Carotid endarterectomy (CEA) for asymptomatic carotid artery disease is advised for patients with low perioperative stroke risk and life expectancy of 3-5 years. We sought to explore the role of risk stratification and postoperative medical management in identifying appropriate asymptomatic candidates for CEA in the end-stage kidney disease (ESKD) population. METHODS: We identified ESKD patients on dialysis from the United States Renal Data System that underwent CEA (2008-2014) for asymptomatic carotid artery disease. We used the Liu comorbidity index as well as a novel risk prediction model based on Cox proportional hazards model to stratify patients. The primary outcome evaluated was 3-year survival, and Kaplan-Meier methods were used to generate survival estimates. We further conducted a subanalysis of patients with Medicare part D data to determine postoperative usage of the following medications: statins, antiplatelets, and antihypertensives. We evaluated the association of medication utilization and 3-year survival using Kaplan-Meier methods and Cox proportional hazards modeling. RESULTS: We analyzed 1,813 patients meeting inclusion criteria. The population was predominantly older (mean age 70.2 ± 9.1), White (84.8%), and had a high prevalence of cardiovascular comorbidities, such as hypertension (90.7%), diabetes (62.5%), and congestive heart failure (35.4%). Among the entire cohort, 23.0% had a Liu comorbidity index ≤8, 35.0% had index 9-12, and 42.0% had index >12. Increasing Liu comorbidity index was associated with worse survival (P < 0.01); however, even the group with Liu index ≤8 had poor 3-year survival of 58.8% (53.9-63.4). The Cox proportional hazards model identified variables for inclusion in the risk model such as age >80 (adjusted hazard ratio [aHR] = 2.49, 95% confidence interval [CI] [1.87-3.33], P < 0.001), congestive heart failure (aHR = 1.31, 95% CI [1.14-1.51], P < 0.001), and Liu comorbidity index >12(aHR = 1.89, 95% CI [1.56-2.28], P < 0.001). The risk score generated ranged from 0 to 6.5, and patients were divided into 3 groups: score ≤2 (43.4%), 2-4 (41.2%), and >4 (15.4%). Increasing risk score was associated with worse survival (P < 0.01) but even the "low-risk" group had 3-year survival of 58.5% (54.9-61.9). Subanalysis of the 1,249 (68.8% of total) patients with part D data found that statins and calcium channel blocker use was associated with improved survival, although observed rates for patients on drug were still low. CONCLUSIONS: The overall long-term survival of ESKD patients undergoing CEA for asymptomatic carotid artery disease is low. Risk stratification and analysis of postoperative medical management did not identify a subgroup of patients with adequate 3-year survival. Hence, the preventive benefits of CEA are not realized in these patients.
引用
- Hafeez MS, Abdul-Malak OM, Eslami MH, et al. Carotid Endarterectomy Should Not Be Recommended to End-Stage Kidney Disease Patients with Asymptomatic Carotid Artery Disease. Ann Vasc Surg. 2023. PMID: 37914071. doi:10.1016/j.avsg.2023.08.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。